COLL News and Press, Collegium Pharmaceutical Inc. From 03/18/24

2024-03-18 14:07:39 ET Summary The healthcare sector is overvalued by about 13% relative to 11-year averages, but overvaluation varies a lot across subsectors. Healthcare equipment has the worst value and quality scores. iShares Global Healthcare ETF is a global alternative to...

2024-03-12 05:00:00 ET Summary The prevailing market sentiment is currently fueled by the allure of "The Magnificent 7" and stocks with high upside potential. Over the last 52 weeks, the S&P 500 is up ~28% compared to the S&P Small-Cap index (~+15%). Small-cap stocks p...

2024-03-11 12:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-23 14:30:03 ET Needham analyst issues UNDERPERFORM recommendation for COLL on February 23, 2024 02:01PM ET. The previous analyst recommendation was Underperform. COLL was trading at $35.54 at issue of the analyst recommendation. The overall analyst consensus : BU...

2024-02-22 21:52:10 ET Collegium Pharmaceutical, Inc. (COLL) Q4 2023 Earnings Conference Call February 22, 2024 04:30 pm ET Company Participants Christopher James - VP of Investor Relations Joseph Ciaffoni - President and CEO Colleen Tupper - EVP and CFO Scot...

2024-02-22 16:41:01 ET More on Collegium Pharmaceutical Stocks To Watch: Energy Market Drama And Financial Earnings Headline Holiday Week Collegium Pharmaceutical Q4 2023 Earnings Preview Collegium issues 2024 outlook, expects record adjusted EBITDA in 2024, shares u...

– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of ...

STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and ...

2024-02-02 08:30:02 ET Jefferies analyst issues UNDERPERFORM recommendation for COLL on February 2, 2024 08:00AM ET. The previous analyst recommendation was Underperform. COLL was trading at $33.47 at issue of the analyst recommendation. The overall analyst consensus : B...

2024-01-17 19:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...